MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives.

MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives.
复制标题

DOI:
10.1016/j.gendis.2014.06.004
复制
发表时间:
2014-09-01
期刊:
影响因子:
6.8
通讯作者:
Chen J
Chen J
中科院分区:
医学2区
文献类型:
--
作者:
Price C;Chen J

文献摘要

被引文献

相似文献

对一类名为 microRNA (miRNA) 的小非编码 RNA 分子的研究增进了我们对癌症生物学的许多基本过程以及肿瘤发生和进展的分子机制的理解。随着越来越多的证据表明 miRNA 可能在几乎所有重要的生物过程中发挥重要的调节作用,miRNA 研究变得越来越有吸引力。纵观过去十年这个领域,很明显我们对 miRNA 的理解仍然相当不完整。随着研究不断揭示癌症治疗功效的机制,很明显 miRNA 有助于对药物治疗的反应,并且其本身会受到药物治疗的修饰。 miRNA研究的一个重要领域是了解miRNA的功能以及肿瘤发生、进展和耐药过程中的相关信号通路,以便能够设计直接针对病理必需的miRNA和/或其靶基因的新型、有效的靶向治疗方法。另一个日益重要的领域是 miRNA 特征在各种癌症的诊断和预后中的应用。随着非编码RNA的研究越来越流行和重要,毫无疑问,未来几年的miRNA研究将提供更令人着迷的结果。
The study of a class of small non-coding RNA molecules, named microRNAs (miRNAs), has advanced our understanding of many of the fundamental processes of cancer biology and the molecular mechanisms underlying tumor initiation and progression. MiRNA research has become more and more attractive as evidence is emerging that miRNAs likely play important regulatory roles virtually in all essential bioprocesses. Looking at this field over the past decade it becomes evident that our understanding of miRNAs remains rather incomplete. As research continues to reveal the mechanisms underlying cancer therapy efficacy, it is clear that miRNAs contribute to responses to drug therapy and are themselves modified by drug therapy. One important area for miRNA research is to understand the functions of miRNAs and the relevant signaling pathways in the initiation, progression and drug-resistance of tumors to be able to design novel, effective targeted therapeutics that directly target pathologically essential miRNAs and/or their target genes. Another area of increasing importance is the use of miRNA signatures in the diagnosis and prognosis of various types of cancers. As the study of non-coding RNAs is increasingly more popular and important, it is without doubt that the next several years of miRNA research will provide more fascinating results.